Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
| Autor: | Val J. Lowe, Ronald C. Petersen, Michelle M. Mielke, Mary M. Machulda, Maria Vassilaki, Clifford R. Jack, Janina Krell-Roesch, Jeremy Syrjanen, Yonas E. Geda, Lesley M. Butler, Teresa J.H. Christianson, Rosebud O. Roberts, Gorazd B. Stokin, David S. Knopman, Martin Traber, Prashanthi Vemuri, Walter K. Kremers |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Aging medicine.medical_specialty Beck Anxiety Inventory Population Anxiety Neuropsychological Tests behavioral disciplines and activities Article lcsh:RC321-571 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Alzheimer Disease Internal medicine mental disorders medicine Humans Cognitive Dysfunction ddc:796 Risk factor education lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Biological Psychiatry Depression (differential diagnoses) Aged Aged 80 and over education.field_of_study Amyloid beta-Peptides Depression Beck Depression Inventory Brain Odds ratio Middle Aged 3. Good health Psychiatry and Mental health Athletic & outdoor sports & games Cross-Sectional Studies Logistic Models 030104 developmental biology Positron-Emission Tomography Female medicine.symptom 030217 neurology & neurosurgery Neuropsychiatric Inventory Questionnaire |
| Zdroj: | Translational Psychiatry, Vol 9, Iss 1, Pp 1-8 (2019) Translational Psychiatry Translational Psychiatry, 9 (123), 1-8 |
| ISSN: | 2158-3188 |
| Popis: | Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|